SARS CoV-2 Omicron (B. 1.1. 529) Recent Updates and Challenges Worldwide

Rina Das; Sherril Yadav; Vishal Sharma; Sumeet Gupta; Anju Goyal; Dinesh Kumar Mehta

doi:10.2174/1871526523666230324113146

SARS CoV-2 Omicron (B. 1.1. 529) Recent Updates and Challenges Worldwide

Infect Disord Drug Targets. 2023;23(5):e240323214950. doi: 10.2174/1871526523666230324113146.

Authors

Rina Das¹, Sherril Yadav¹, Vishal Sharma¹, Sumeet Gupta¹, Anju Goyal², Dinesh Kumar Mehta¹

Affiliations

¹ MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, HR, 133207, India.
² Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

PMID: 36967463
DOI: 10.2174/1871526523666230324113146

Abstract

The current world is plagued by unpredictability as a result of various COVID-19 variants. The current variants of concern (VOCs) are B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617/B.1.617.2(Delta). WHO classified two variants, delta (B.1.617.2) and omicron (B.1.1.529), as having highly mutable strikes. The WHO predicted that it would be more dangerous than previous variants due to its mutatable capability. The Omicron variant of coronavirus has caused widespread disruption, with countries struggling to manage the massive number of infections. Due to its unique properties, such as protein structure, symptoms, transmission, and epidemiology, this review aims to compare omicron to other variants. Furthermore, we have highlighted vaccines that have been used to combat this pandemic.

Keywords: COVID-19; VOCs; mutation; omicron; spreadability; vaccine..

Publication types

Review

MeSH terms

COVID-19*
Humans
Pandemics / prevention & control
SARS-CoV-2*

Supplementary concepts

SARS-CoV-2 variants